REG - e-Therapeutics plc - Immuno-Oncology Research Collaboration with iTeos

E-TherapeuticsAnnouncement

05/04/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220405:nRSE2180Ha&default-theme=true

RNS Number : 2180H  e-Therapeutics plc  05 April 2022

e-therapeutics plc

("e-therapeutics" or "the Company")

Immuno-Oncology Research Collaboration with iTeos Therapeutics

 

Oxford, UK, 5 April 2022 - e-therapeutics plc (AIM: ETX; OTCQX: ETXPF), a
specialist in computational drug discovery with a focus on developing RNA
interference ("RNAi") therapeutics, announces that it has entered into a
research collaboration agreement with iTeos Therapeutics, Inc. ("iTeos",
Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the
discovery and development of a new generation of highly differentiated
immuno-oncology therapeutics for patients. The collaboration will focus on the
discovery of novel therapeutic approaches and targets in immuno-oncology.
e-therapeutics will remain free to explore additional collaborations in the
space.

Under the terms of the agreement, e-therapeutics will receive upfront and
near-term cash payments material to the revenue of the Company. The Company is
also eligible to receive undisclosed milestone payments through pre-clinical
and clinical development, in addition to regulatory milestones per programme.

The collaboration will combine key expertise from both companies, including
e-therapeutics' computational platform and iTeos' proprietary assays. iTeos is
a leader in the immuno-oncology space developing next-generation therapies for
patients with cancer. e-therapeutics' computational platform and in silico
predictions have been experimentally validated across multiple therapeutic
areas (including in immuno-oncology), demonstrating its ability to
reproducibly assess millions of therapeutic hypotheses, gain insights into
lesser-known mechanistic disease processes and identify therapeutic
interventions with a higher probability of success than standard drug
discovery processes. This translates into a more efficient drug discovery
process with greater scope for novelty, as well as significant time and cost
savings.

 

Ali Mortazavi, Chief Executive Officer of e-therapeutics, commented:

"We are extremely pleased to partner with iTeos to help identify highly
differentiated immuno-oncology medicines for patients. We believe that our
computational platform can discover novel therapeutic approaches for iTeos to
prosecute in a hugely promising area of cancer treatment. This collaboration
provides further validation of the value of our network-driven, disease
agnostic computational platform, which we will continue to leverage as we
build our in-house RNAi based pipeline."

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 which has been incorporated into UK law by the European
Union (Withdrawal) Act 2018.

 

 

Enquiries:

 

 e-therapeutics plc
 Ali Mortazavi, CEO                                 Tel: +44 (0)1993 883 125

 Laura Roca-Alonso, CBO                             www.etherapeutics.co.uk

 SP Angel Corporate Finance LLP                     Tel: +44(0)20 3470 0470
 Nominated Adviser and Broker
 Matthew Johnson/Caroline Rowe (Corporate Finance)
 Vadim Alexandre/Rob Rees (Corporate Broking)

 

About iTeos Therapeutics, Inc.

iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering
the discovery and development of a new generation of highly differentiated
immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its
deep understanding of tumour immunology and immunosuppressive pathways to
design novel product candidates with the potential to fully restore the immune
response against cancer. The Company's innovative pipeline includes two
clinical-stage programs targeting novel, validated immuno-oncology pathways
designed with optimized pharmacologic properties for improved clinical
outcomes. The first antibody product candidate, EOS-448, is a high affinity,
potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance
the anti-tumour response through a multifaceted immune modulatory mechanism,
currently progressing in multiple indications in collaboration with GSK. The
Company is also advancing inupadenant, a next-generation adenosine A2A
receptor antagonist tailored to overcome cancer immunosuppression into
proof-of concept trials in several indications following encouraging
single-agent activity in Phase 1. iTeos Therapeutics is headquartered in
Watertown, MA with a research center in Gosselies, Belgium.

 

About e-therapeutics plc

e-therapeutics plc is a UK-based company integrating computational power and
biology to accelerate the discovery of life-transforming medicines. The
Company has developed and validated a powerful, disease and modality agnostic
computational approach to drug discovery, leveraging its industry-leading
expertise in network biology to fully capture and interrogate human disease
complexity.

 

The Company's multi-disciplinary team builds computational models of
biological functions to transform the search for new medicines, interventions,
mechanisms and genetic support. Its biology-led in silico laboratory enables
rapid hypothesis generation and phenotypic screening of millions of compounds
leading to 100-1000x higher hit rates in the wet lab and successful mode of
action elucidation. Novel targets can also be identified, prioritised and
assessed. Harnessing internal target gene discoveries, e-therapeutics is
currently building an in-house pipeline of RNAi based medicines, using its
proprietary GalNAc-siRNA technology.

 

e-therapeutics has deployed and validated its disease-agnostic computational
drug discovery platform both in house and with partners, including Novo
Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RESZZGGDVDNGZZM